SIGN UP
LOG IN
Releases
Sihuan Pharmaceutical Holdings Group
--
--
0.00%
  • All
More
About Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of pharmaceutical products and aesthetic products. The Company operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The Company conducts its business in the domestic and overseas markets.
More

FAQ

Fee ScheduleOpen AccountDeposit & WithdrawalTrading

Terms & Conditions

Client AgreementPrivacy PolicyData DisclaimerSecurity Tips

About Webull

About usWebull PromotionsContact informationAnnouncements

Contact Us

Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.